Olink Bioscience appoints Simon Fredriksson Ph.D. as Executive Vice President

Uppsala, Sweden, June 15, 2011 – Simon Fredriksson co-founder and CSO of Olink AB has today been promoted to executive Vice President. With the new appointment follow increased responsibilities for global business development and external research collaborations.

Dr Fredriksson, one of the founding scientists of Olink has over the last 7 years significantly contributed to the development of Olink´s product platform Duolink® and Proseek® and the company´s research portfolio. He has also been increasingly involved in the company´s business development activities, external research collaboration and the strategic planning processes. As recognition for his new and expanded responsibilities Olink Board of Directors yesterday decided to promote Dr Fredriksson to Executive Vice President of Olink AB as of June 15, 2011.

“We are pleased to see Simon in this new roll and feel confident that the appointment will further stimulate Simon to contribute to the development of our business” says Patrik Dahlén, Chairmen of the Board.

Commenting on his appointment Dr Fredriksson said “I feel very inspired to get the support from the board to more directly influence the directions of the company – this is a great opportunity for me to contribute to our further success”.

“I am looking forward working even closer with Simon now in his new capacity and to generate important opportunities for Olink” says Björn Ekström, President and CEO. 

About Olink AB
Olink Bioscience is commercializing cutting-edge technologies for analysis of proteins and nucleic acids revealing new insights into basic science, drug development, and diagnostics.  Our products are available worldwide through a network of distributors and through our webshop. The Duolink product line enables users to visualize and quantify individual proteins, their interactions and modifications, in unmodified cells and tissues. Proseek is an open assay development reagent kit for analyzing proteins in only 1 µl of serum or plasma sample with high sensitivity.

Olink’s molecular technologies are also commercialized through partnerships with industry leading organizations such as Affymetrix, Life Technologies, and through Olink spin-out companies Halo Genomics and Qlinea. Olink Bioscience was founded in 2004 and is headquartered in Uppsala, Sweden

For information please contact:
Björn Ekström                                                                
CEO and President              
Olink Bioscience                                                            
Phone: +46 (0)18 444 39 70                        
email: info@olink.com